ROHLEDER, Ondřej, Peter MÚDRY, Jakub NERADIL, Hana NOSKOVÁ, Ondřej SLABÝ and Jaroslav ŠTĚRBA. Letter to Editor: FS Kaplan, et al., Early clinical observations on the use of imatinibmesylate in FOP: A report of seven cases, Bone (2017). Bone. NEW YORK: Elsevier, 2018, vol. 116, NOV, p. 171. ISSN 8756-3282. Available from: https://dx.doi.org/10.1016/j.bone.2018.08.003.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Letter to Editor: FS Kaplan, et al., Early clinical observations on the use of imatinibmesylate in FOP: A report of seven cases, Bone (2017)
Authors ROHLEDER, Ondřej (203 Czech Republic, belonging to the institution), Peter MÚDRY (203 Czech Republic, belonging to the institution), Jakub NERADIL (203 Czech Republic, belonging to the institution), Hana NOSKOVÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution) and Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution).
Edition Bone, NEW YORK, Elsevier, 2018, 8756-3282.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30202 Endocrinology and metabolism
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.360
RIV identification code RIV/00216224:14740/18:00104863
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1016/j.bone.2018.08.003
UT WoS 000447232100020
Keywords in English OSSIFICANS PROGRESSIVA FOP
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 21/3/2019 14:46.
Abstract
We read with great interest the article published by F.S. Kaplan et al. Early clinical observations on the use of imatinibmesylate in FOP: A report of seven cases, Bone (2017). Following this [1] we would like to present a case report of one our patient with FOP successfully responding to sunitinib.
PrintDisplayed: 26/7/2024 16:30